ConvaTec Group PLC
Latest From ConvaTec Group PLC
Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.
Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.
Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.
The global advanced wound-care market is expected to reach $10.4bn by 2020, driven by massive competition, and forcing companies to innovate constantly to address the rising prevalence of chronic wound injuries, diabetic foot ulcers and burns. While regulatory and reimbursement challenges prevail, opportunities in this highly segmented market, in particular, in the advanced wound-dressings sector, are vast, with double-digit revenue growth potential.
- Consumables, Central Supplies
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Rehabilitation Equipment and Devices
- Surgical Equipment & Devices
- Therapeutic Areas
- Gynecological, Urological
- Metabolic Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Wound Healing & Tissue Repair
- Western Europe
- Parent & Subsidiaries
- ConvaTec Group PLC
- Senior Management
Rick Anderson, Interim CEO
Frank Schulkes, CFO
Donal Balfe, EVP, Global Operations
- Contact Info
ConvaTec Group PLC
Phone: 118 952 8123
23 Forbury Rd.
3 Forbury Pl.
Reading, NC RG1 3JH
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.